Adaptimmune Therapeutics Plc (ADAP) — Capital Reinvestment Ratio
Latest as of June 2024:
0.02x
Adaptimmune Therapeutics Plc (ADAP) has a Capital Reinvestment Ratio of 0.02x as of June 2024, meaning it reinvests 0% of its operating cash flow ($47.39 Million) in capital expenditures ($754.55K). See free cash flow generation of Adaptimmune Therapeutics Plc to measure how efficiently the company converts operating cash flow to free cash.
Capital Reinvestment Ratio
0.02x
Capex / Operating Cash Flow
Operating Cash Flow
$47.39 Million
USD
Capital Expenditures
$754.55K
USD
Data as of
Jun 2024
Most recent filing
Adaptimmune Therapeutics Plc Capital Reinvestment Ratio (2013–2021)
This chart tracks Adaptimmune Therapeutics Plc's Capital Reinvestment Ratio across 2 annual periods.
Annual Capital Reinvestment Ratio for Adaptimmune Therapeutics Plc (2013–2021)
Year-by-year Capital Reinvestment Ratio for Adaptimmune Therapeutics Plc from 2013 to 2021. For live market cap and broader valuation context, see market cap of Adaptimmune Therapeutics Plc.
| Year | Reinvestment Ratio | Operating CF (USD) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2021 | 0.82x | $10.73 Million | $8.78 Million | ▲ +2002.4% |
| 2013 | 0.04x | $37.23 Million | $1.45 Million | — |
Capital Reinvestment Ratio = ABS(Capital Expenditures) / Operating Cash Flow